Spotlight on Hematology

Noopur Raje, MD
Credits: 0.5 CME
Expert Insights: New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma
Noopur Raje, MD
Postgraduate Institute for Medicine

Expert Insights: New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 5, 2021
Expires: August 5, 2022
30 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate treatment approaches for patients with relapsed and/or refractory MM specifically the decision to include a monoclonal antibody or antibody-drug conjugate, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will highlight the most clinically relevant data and its potential impact on current and future strategies for the treatment of relapsed/refractory multiple myeloma.

Statement of Educational Need

Multiple myeloma (MM) is a clonal plasma cell malignant neoplasm that accounts for 1% of all cancers and ~10% of all hematologic malignancies. The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data of investigational agents will require expert guidance and interpretation of newly released data.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Noopur Raje, MD
Professor of Medicine, Harvard Medical School
Director, Multiple Myeloma Program, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Consultant/Advisory Board: Celgene, Takeda, Amgen Inc., Novartis, Janssen, Bristol Myers Squibb Company, Merck, Pfizer, Bluebird Bio, Caribou Biosciences, Immuneel Therapeutics
Research Funding: Bluebird Bio

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Oncopeptides and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 5, 2021
Expires: August 5, 2022
30 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate treatment approaches for patients with relapsed and/or refractory MM specifically the decision to include a monoclonal antibody or antibody-drug conjugate, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will highlight the most clinically relevant data and its potential impact on current and future strategies for the treatment of relapsed/refractory multiple myeloma.

Statement of Educational Need

Multiple myeloma (MM) is a clonal plasma cell malignant neoplasm that accounts for 1% of all cancers and ~10% of all hematologic malignancies. The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data of investigational agents will require expert guidance and interpretation of newly released data.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Noopur Raje, MD
Professor of Medicine, Harvard Medical School
Director, Multiple Myeloma Program, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Consultant/Advisory Board: Celgene, Takeda, Amgen Inc., Novartis, Janssen, Bristol Myers Squibb Company, Merck, Pfizer, Bluebird Bio, Caribou Biosciences, Immuneel Therapeutics
Research Funding: Bluebird Bio

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Oncopeptides and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Hematology Presentations

1.0 CME / CNE / CPE
Rush University Medical Center
Management of Waldenström’s Macroglobulinemia in the Era of Targeted Therapies

Management of Waldenström’s Macroglobulinemia in the Era of Targeted Therapies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 13, 2022
Expires: May 12, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
  • Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
  • Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Steven P. Treon, MD, MA, PhD
Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA

Dr. Treon has provided the following disclosure information:
  • Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
  • Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 13, 2022
Expires: May 12, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
  • Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
  • Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Steven P. Treon, MD, MA, PhD
Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA

Dr. Treon has provided the following disclosure information:
  • Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
  • Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Matthew S. Davids, MD, MMSc
1.0 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Optimizing Outcomes with the Latest Advances in Small Molecule Inhibitors for Chronic Lymphocytic Leukemia

Expert Perspectives on Optimizing Outcomes with the Latest Advances in Small Molecule Inhibitors for Chronic Lymphocytic Leukemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 12, 2022
Expires: April 11, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
  2. Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
  3. Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
  4. Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.

Faculty

Matthew S. Davids, MD, MMSc
Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis


Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 12, 2022
Expires: April 11, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
  2. Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
  3. Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
  4. Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.

Faculty

Matthew S. Davids, MD, MMSc
Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis


Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Matthew S. Davids, MD, MMSc
0.75 CME
The University of Nebraska Medical Center
Expert Guidance on the Optimal Use of Current and Emerging BTK Inhibitors for Patients with CLL

Expert Guidance on the Optimal Use of Current and Emerging BTK Inhibitors for Patients with CLL

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: March 23, 2022
Expires: March 23, 2023
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Identify various disease- and patient-related factors that impact the selection of BTK inhibitor use in patients with CLL
  • Evaluate clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
  • Assess trial results of investigational BTK-based approaches to the treatment of CLL, including monotherapy and combination approaches
  • Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, adverse event management, as well as oral adherence strategies

Activity Description

This webcast will provide expert guidance on how to correctly use current and emerging BTK inhibitors safely and effectively for patients with CLL and plan strategies for optimal integration of these novel agents into practice.

Statement of Educational Need

Major advances in the diagnosis and treatment of CLL have occurred in the past decade. In the future, studies will continue to BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.

Agenda

  • Welcome & Introductions
  • Rationale for Targeting Bruton Tyrosine Kinase (BTK) in Patients With CLL
  • Currently Available BTK Inhibitor-Based Strategies: Phase 3 Studies
  • Future Directions and Emerging Data of BTK Inhibitor Therapy
  • Considerations for Improving Patient Outcomes
  • Conclusions

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Moderator
Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.

Statement of Commercial Support

Educational grant support provided by BeiGene, Ltd. and Pharmacyclics LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: March 23, 2022
Expires: March 23, 2023
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Identify various disease- and patient-related factors that impact the selection of BTK inhibitor use in patients with CLL
  • Evaluate clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
  • Assess trial results of investigational BTK-based approaches to the treatment of CLL, including monotherapy and combination approaches
  • Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, adverse event management, as well as oral adherence strategies

Activity Description

This webcast will provide expert guidance on how to correctly use current and emerging BTK inhibitors safely and effectively for patients with CLL and plan strategies for optimal integration of these novel agents into practice.

Statement of Educational Need

Major advances in the diagnosis and treatment of CLL have occurred in the past decade. In the future, studies will continue to BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.

Agenda

  • Welcome & Introductions
  • Rationale for Targeting Bruton Tyrosine Kinase (BTK) in Patients With CLL
  • Currently Available BTK Inhibitor-Based Strategies: Phase 3 Studies
  • Future Directions and Emerging Data of BTK Inhibitor Therapy
  • Considerations for Improving Patient Outcomes
  • Conclusions

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Moderator
Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.

Statement of Commercial Support

Educational grant support provided by BeiGene, Ltd. and Pharmacyclics LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Benjamin Derman, MD
1.0 CME / CNE / CPE
Rush University Medical Center
Understanding Evolving Treatment Strategies in Newly Diagnosed Multiple Myeloma Patients

Understanding Evolving Treatment Strategies in Newly Diagnosed Multiple Myeloma Patients

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: March 21, 2022
Expires: March 20, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with newly diagnosed multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Review key advances in the treatment and management of newly diagnosed multiple myeloma (NDMM) and their impact on clinical practice
  • Incorporate guideline-directed evidence-based best practices, taking into consideration patient-, disease-, and treatment-related factors to individualize care for NDMM patients
  • Describe promising emerging therapies for the treatment of NDMM and their potential roles in the context of existing NDMM treatment paradigms
  • Identify strategies to incorporate optimal treatment administration for NDMM patients

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating newly diagnosed multiple myeloma patients. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With changing guidelines, evolving concepts in diagnosis, treatment, and management of newly diagnosed multiple myeloma (NDMM), recently approved combination regimens and delivery formulations, and the introduction of novel agents and combination to the clinic, there are ongoing questions regarding the optimal treatment strategies for patients. Clinicians require expert guidance to actualize recent clinical advances into real-world clinical practice to optimize outcomes for their NDMM patients.

Faculty

Benjamin Derman, MD
Assistant Professor of Medicine
University of Chicago Medical Center
Chicago, Illinois

Dr. Derman has provided the following disclosure information:
Advisory Board: Sanofi, Janssen

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and the Leukemia Research Foundation.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: March 21, 2022
Expires: March 20, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with newly diagnosed multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Review key advances in the treatment and management of newly diagnosed multiple myeloma (NDMM) and their impact on clinical practice
  • Incorporate guideline-directed evidence-based best practices, taking into consideration patient-, disease-, and treatment-related factors to individualize care for NDMM patients
  • Describe promising emerging therapies for the treatment of NDMM and their potential roles in the context of existing NDMM treatment paradigms
  • Identify strategies to incorporate optimal treatment administration for NDMM patients

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating newly diagnosed multiple myeloma patients. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With changing guidelines, evolving concepts in diagnosis, treatment, and management of newly diagnosed multiple myeloma (NDMM), recently approved combination regimens and delivery formulations, and the introduction of novel agents and combination to the clinic, there are ongoing questions regarding the optimal treatment strategies for patients. Clinicians require expert guidance to actualize recent clinical advances into real-world clinical practice to optimize outcomes for their NDMM patients.

Faculty

Benjamin Derman, MD
Assistant Professor of Medicine
University of Chicago Medical Center
Chicago, Illinois

Dr. Derman has provided the following disclosure information:
Advisory Board: Sanofi, Janssen

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and the Leukemia Research Foundation.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Rafael Fonseca, MD
1.0 CME / CNE
Integrity Continuing Education, Inc.
Utilizing Real World Evidence: Focus on Multiple Myeloma in Older Adults

Utilizing Real World Evidence: Focus on Multiple Myeloma in Older Adults

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour(s)
Released: February 28, 2022
Expires: February 28, 2023
60 minutes to complete

Provider Statement

This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.

This CE activity for ANCC credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This educational activity has been designed to meet the needs of hematologist/oncologists, medical oncologists, physician assistants, nurse practitioners, and advanced practice nurses who treat and manage patients with multiple myeloma.

Program Overview

Evidence has demonstrated that undertreatment of fit elderly multiple myeloma (MM) patients occurs more frequently than overtreatment. While overtreatment of frail MM patients can induce unnecessary morbidity and mortality, an appropriate assessment for frailty is key to determine whether the patient is actually frail or in fact fit. This step ensures optimal outcomes and improved health-related quality of life.

This In The Clinic activity features a discussion on proper assessment of older MM patients, different scoring systems, the role of real-world evidence (RWE), and trials that support the use of RWE. The clinical case scenarios will allow participants to utilize information from the discussions. A simplified, downloadable frailty scoring tool is also included.

Learning Objectives

  • ASSESS patients for fitness/frailty to select appropriate treatment based on individual results
  • EVALUATE patient data, including real-world data such as patient reported outcomes and assessment scores, to determine the most appropriate treatment regimens
  • IDENTIFY strategies for managing toxicities and comorbidities associated with MM in older patients

Moderator

Rafael Fonseca, MD
Chief Innovation Officer
Getz Family Professor of Cancer
Department of Hematology/Oncology
Distinguished Mayo Clinic Investigator
Phoenix, Arizona

Faculty Presenters

Faith Davies, MBBCh, MRCP, MD, FRCPath
Professor of Medicine
Director, Myeloma Clinical Program
Perlmutter Cancer Center
NYU Langone Health
New York, New York


Robert Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Case Study Development

Hira Mian, MD
Hematology Oncologist
Juravinski Cancer Centre
Assistant Professor of Oncology
McMaster University
Ontario, Canada

Disclosure of Conflicts of Interest

Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Faith Davies, MBBCh, MRCP, MD, FRCPath
Consultant: AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Takeda

Rafael Fonseca, MD
Consultant: AbbVie, Aduro, Amgen, Bayer, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Juno, Kite, Merck, Novartis, OncoTracker, Pharmacyclics, Sanofi, Takeda
Scientific Advisory Boards: Adaptive Biotechnologies, OncoTracker

Hira Mian, MD
Research Funding: Janssen
Advisor/Speaker: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, Takeda

Robert Orlowski, MD, PhD
Consultant: AbbVie, Bristol Myers Squibb, GlaxoSmithKline Biologicals, Karyopharm Therapeutics, Inc., Meridian Therapeutics, Monte Rosa Therapeutics, Neoleukin Corporation, Oncopeptides AB, Regeneron Pharmaceuticals, Inc.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Samuel Ciociola, Donna Fausak, Andrea Funk, Liddy Knight, David Lemler, PhD, and Rhys Williams, RN, MSN, FNP, reported that they or their spouses/life partners have no financial relationships or relationships to products or devices with ineligible companies related to the content of this CE activity.

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CE/CME credit for this activity. During the period of February 28, 2022, through February 28, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour(s)
Released: February 28, 2022
Expires: February 28, 2023
60 minutes to complete

Provider Statement

This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.

This CE activity for ANCC credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This educational activity has been designed to meet the needs of hematologist/oncologists, medical oncologists, physician assistants, nurse practitioners, and advanced practice nurses who treat and manage patients with multiple myeloma.

Program Overview

Evidence has demonstrated that undertreatment of fit elderly multiple myeloma (MM) patients occurs more frequently than overtreatment. While overtreatment of frail MM patients can induce unnecessary morbidity and mortality, an appropriate assessment for frailty is key to determine whether the patient is actually frail or in fact fit. This step ensures optimal outcomes and improved health-related quality of life.

This In The Clinic activity features a discussion on proper assessment of older MM patients, different scoring systems, the role of real-world evidence (RWE), and trials that support the use of RWE. The clinical case scenarios will allow participants to utilize information from the discussions. A simplified, downloadable frailty scoring tool is also included.

Learning Objectives

  • ASSESS patients for fitness/frailty to select appropriate treatment based on individual results
  • EVALUATE patient data, including real-world data such as patient reported outcomes and assessment scores, to determine the most appropriate treatment regimens
  • IDENTIFY strategies for managing toxicities and comorbidities associated with MM in older patients

Moderator

Rafael Fonseca, MD
Chief Innovation Officer
Getz Family Professor of Cancer
Department of Hematology/Oncology
Distinguished Mayo Clinic Investigator
Phoenix, Arizona

Faculty Presenters

Faith Davies, MBBCh, MRCP, MD, FRCPath
Professor of Medicine
Director, Myeloma Clinical Program
Perlmutter Cancer Center
NYU Langone Health
New York, New York


Robert Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Case Study Development

Hira Mian, MD
Hematology Oncologist
Juravinski Cancer Centre
Assistant Professor of Oncology
McMaster University
Ontario, Canada

Disclosure of Conflicts of Interest

Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Faith Davies, MBBCh, MRCP, MD, FRCPath
Consultant: AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Takeda

Rafael Fonseca, MD
Consultant: AbbVie, Aduro, Amgen, Bayer, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Juno, Kite, Merck, Novartis, OncoTracker, Pharmacyclics, Sanofi, Takeda
Scientific Advisory Boards: Adaptive Biotechnologies, OncoTracker

Hira Mian, MD
Research Funding: Janssen
Advisor/Speaker: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, Takeda

Robert Orlowski, MD, PhD
Consultant: AbbVie, Bristol Myers Squibb, GlaxoSmithKline Biologicals, Karyopharm Therapeutics, Inc., Meridian Therapeutics, Monte Rosa Therapeutics, Neoleukin Corporation, Oncopeptides AB, Regeneron Pharmaceuticals, Inc.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Samuel Ciociola, Donna Fausak, Andrea Funk, Liddy Knight, David Lemler, PhD, and Rhys Williams, RN, MSN, FNP, reported that they or their spouses/life partners have no financial relationships or relationships to products or devices with ineligible companies related to the content of this CE activity.

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CE/CME credit for this activity. During the period of February 28, 2022, through February 28, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Gilles Salles, MD, PhD
1.0 CME
Postgraduate Institute for Medicine
On-Topic Virtual Roundtable™: From R-CHOP to Beyond – Emerging Strategies to Prevent Disease Progression in Patients with Newly Diagnosed DLBCL

On-Topic Virtual Roundtable™: From R-CHOP to Beyond – Emerging Strategies to Prevent Disease Progression in Patients with Newly Diagnosed DLBCL

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: February 22, 2022
Expires: February 22, 2023
60 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with DLBCL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Appraise currently available multiagent chemo-immunotherapy approaches that are traditionally used for the treatment of patients with newly diagnosed DLBCL
  • Assess the benefits and limitations of current therapeutic regimens for patients with newly diagnosed DLBCL and the need for novel approaches
  • Evaluate the safety and efficacy of clinical trial results evaluating novel approaches to the upfront treatment of patients with DLBCL, including the use of novel agents and combinations

Activity Description

On-Topic Virtual Roundtable™ is an on-demand, accredited continuing education activity featuring three experts who provide expert summary and guidance on the use of current and emerging multiagent treatment regimens for patients with newly diagnosed DLBCL. This roundtable will summarize traditionally used chemo-immunotherapy regimens, limitations with currently available therapies, clinical data of emerging agents and combinations, and strategies for integrating novel regimens into practice as they become available.

Statement of Educational Need

The current standard of care of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in 2021 remains chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Although this modality is safe and effective, up to 45%-50% of patients will relapse. This underscores the need for novel treatment approaches for these patients with newly diagnosed disease. This activity will discuss ongoing efforts to improve upon the standard of care of patients with DLBCL to lengthen progression-free survival (PFS) and improve patient outcomes.

Topics Discussed

  • Introduction and Overview of Traditional Regimens
  • Limitations of Traditional Therapies
  • Emerging Approaches for Frontline Treatment
  • Integrating Novel Approaches in Clinical Practice & Key Takeaways

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
Gilles Salles, MD, PhD

Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Consultant: AbbVie, Bayer, BeiGene, BMS/Celgene, Epizyme, Genentech/Roche, Genmab, Incyte, Janssen, Kite/Gilead, Loxo, Milteniy, MorphoSys, Novartis, Rapt, Regeneron, Takeda
Stock Ownership: Owkin


Christopher Flowers, MD, MS
Department Chair, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Grant/Research Support: AbbVie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation
Consultant/Advisory Board: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum


Laurie Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Vancouver, Canada

Grant/Research Support: Roche/Genentech, Teva
Consultant/Advisory Board: AbbVie, Acerta, Arigen, Apobiologix, AstraZeneca, Bristol Myers Squibb, Celgene, Gilead, Incyte, Janssen, Kite, Karyopharm, Merck, MorphoSys, Roche/Genentech, Teva, Takeda, TG Therapeutics, Verastem


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: February 22, 2022
Expires: February 22, 2023
60 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with DLBCL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Appraise currently available multiagent chemo-immunotherapy approaches that are traditionally used for the treatment of patients with newly diagnosed DLBCL
  • Assess the benefits and limitations of current therapeutic regimens for patients with newly diagnosed DLBCL and the need for novel approaches
  • Evaluate the safety and efficacy of clinical trial results evaluating novel approaches to the upfront treatment of patients with DLBCL, including the use of novel agents and combinations

Activity Description

On-Topic Virtual Roundtable™ is an on-demand, accredited continuing education activity featuring three experts who provide expert summary and guidance on the use of current and emerging multiagent treatment regimens for patients with newly diagnosed DLBCL. This roundtable will summarize traditionally used chemo-immunotherapy regimens, limitations with currently available therapies, clinical data of emerging agents and combinations, and strategies for integrating novel regimens into practice as they become available.

Statement of Educational Need

The current standard of care of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in 2021 remains chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Although this modality is safe and effective, up to 45%-50% of patients will relapse. This underscores the need for novel treatment approaches for these patients with newly diagnosed disease. This activity will discuss ongoing efforts to improve upon the standard of care of patients with DLBCL to lengthen progression-free survival (PFS) and improve patient outcomes.

Topics Discussed

  • Introduction and Overview of Traditional Regimens
  • Limitations of Traditional Therapies
  • Emerging Approaches for Frontline Treatment
  • Integrating Novel Approaches in Clinical Practice & Key Takeaways

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
Gilles Salles, MD, PhD

Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Consultant: AbbVie, Bayer, BeiGene, BMS/Celgene, Epizyme, Genentech/Roche, Genmab, Incyte, Janssen, Kite/Gilead, Loxo, Milteniy, MorphoSys, Novartis, Rapt, Regeneron, Takeda
Stock Ownership: Owkin


Christopher Flowers, MD, MS
Department Chair, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Grant/Research Support: AbbVie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation
Consultant/Advisory Board: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum


Laurie Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Vancouver, Canada

Grant/Research Support: Roche/Genentech, Teva
Consultant/Advisory Board: AbbVie, Acerta, Arigen, Apobiologix, AstraZeneca, Bristol Myers Squibb, Celgene, Gilead, Incyte, Janssen, Kite, Karyopharm, Merck, MorphoSys, Roche/Genentech, Teva, Takeda, TG Therapeutics, Verastem


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Caron Jacobson, MD
1.0 CME / CNE / CPE
Rush University Medical Center
Emerging Cellular and Targeted Therapy Options for the Management of Large B-Cell Lymphoma

Emerging Cellular and Targeted Therapy Options for the Management of Large B-Cell Lymphoma

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with large B-cell lymphoma.

Learning Objectives

After completing this program, participants should be able to:

  • Analyze the latest developments in cellular and targeted therapies used for the treatment of LBCL, as well as how these approaches fit into the current treatment landscape
  • Assess ongoing clinical trials using cellular and targeted therapies to treat LBCL, including studies focused on using cellular and targeted therapies in the frontline setting
  • Outline adverse effects associated with cellular and targeted therapies and describe effective approaches to appropriately manage these effects
  • Identify patients with LBCL who are candidates for cellular and targeted therapy and formulate individualized treatment plans based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of large B-cell lymphoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with LBCL and the clinical utility of agents that could significantly impact patient outcomes. With the recent advances in cellular and targeted therapies for LBCL, the use of approved and investigational agents is anticipated to expand over the coming years. Clinicians must be up-to-date on the efficacy and safety profile of currently approved and investigational agents to offer patients the best clinical outcomes.

Faculty

Caron Jacobson, MD
Medical Director, Immune Effector Cell Therapy Program
Senior Physician
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Dr. Jacobson has provided the following disclosure information:
  • Consulting for Kite/Gilead, BMS/Celgene, Novartis, Precision Biosciences, Nkarta, Lonza, bluebird bio, AbbVie, Ipsen
  • Research funding from Kite/Gilead, Pfizer

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from ADC Therapeutics Inc., Bristol Myers Squibb, Genentech, Genmab US, Inc., and Incyte who have had no influence on, control of, nor input into the development or performance of the activity.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with large B-cell lymphoma.

Learning Objectives

After completing this program, participants should be able to:

  • Analyze the latest developments in cellular and targeted therapies used for the treatment of LBCL, as well as how these approaches fit into the current treatment landscape
  • Assess ongoing clinical trials using cellular and targeted therapies to treat LBCL, including studies focused on using cellular and targeted therapies in the frontline setting
  • Outline adverse effects associated with cellular and targeted therapies and describe effective approaches to appropriately manage these effects
  • Identify patients with LBCL who are candidates for cellular and targeted therapy and formulate individualized treatment plans based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of large B-cell lymphoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with LBCL and the clinical utility of agents that could significantly impact patient outcomes. With the recent advances in cellular and targeted therapies for LBCL, the use of approved and investigational agents is anticipated to expand over the coming years. Clinicians must be up-to-date on the efficacy and safety profile of currently approved and investigational agents to offer patients the best clinical outcomes.

Faculty

Caron Jacobson, MD
Medical Director, Immune Effector Cell Therapy Program
Senior Physician
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Dr. Jacobson has provided the following disclosure information:
  • Consulting for Kite/Gilead, BMS/Celgene, Novartis, Precision Biosciences, Nkarta, Lonza, bluebird bio, AbbVie, Ipsen
  • Research funding from Kite/Gilead, Pfizer

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from ADC Therapeutics Inc., Bristol Myers Squibb, Genentech, Genmab US, Inc., and Incyte who have had no influence on, control of, nor input into the development or performance of the activity.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

John O. Mascarenhas, MD
0.5 CME
Postgraduate Institute for Medicine
Podium to Practice: Recent Updates on the Treatment of Myeloproliferative Neoplasms – Highlights from the 2021 Hematology Annual Meeting

Podium to Practice: Recent Updates on the Treatment of Myeloproliferative Neoplasms – Highlights from the 2021 Hematology Annual Meeting

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 2, 2022
Expires: February 2, 2023
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MPNs.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Identify treatment goals for myeloproliferative neoplasms that incorporate disease-modifying therapies based on the latest available clinical data
  • Develop strategies to incorporate disease-modifying therapies and strive for deeper responses in patients with myeloproliferative neoplasms
  • Discuss the emerging results of clinical trials that are investigating therapies in myeloproliferative neoplasms

Activity Description

Podium to Practice™ is an exclusive accredited continuing education activity featuring two myeloproliferative neoplasms (MPN) experts who provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASH Annual Meeting.

Statement of Educational Need

In recent years, there have been major advances in our understanding of the underlying genetic changes that drive the development of MPNs, particularly with the discovery of mutations in the Janus kinase 2 (JAK2), thrombopoietin receptor (MPL), and calreticulin (CALR) genes. JAK inhibitors represent a shift in the treatment paradigm from largely managing lifestyle and cardiovascular risk factors and addressing the effects of the disease, to attempting modification of the disease process itself. Despite these advances, nearly all treatment options for MPNs are not curative. Therefore, reduction of symptom burden, and thereby the impact of MPNs on QoL, is critical and should be considered a major goal of treatment. With a robust pipeline of new disease-modifying therapies, a clinical question of whether to aim for a deeper response is emerging.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
John O. Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Consultant: AbbVie, Bristol Myers Squibb, Celgene Corporation, Constellation, CTI BioPharma, Geron, Incyte Corporation, Kartos, Novartis, PharmaEssentia, Roche, Sierra ONC
Contracted Research: AbbVie, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma, Geron, Incyte Corporation, Kartos, Novartis, PharmaEssentia, Roche


Alessandro Vannucchi, MD
Professor of Hematology
Careggi University Hospital
University of Florence
Florence, Italy

Consultant: AbbVie, Blueprint, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Roche
Contracted Research: AbbVie, Blueprint, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Roche

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by an independent educational grant from CTI BioPharma.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 2, 2022
Expires: February 2, 2023
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MPNs.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Identify treatment goals for myeloproliferative neoplasms that incorporate disease-modifying therapies based on the latest available clinical data
  • Develop strategies to incorporate disease-modifying therapies and strive for deeper responses in patients with myeloproliferative neoplasms
  • Discuss the emerging results of clinical trials that are investigating therapies in myeloproliferative neoplasms

Activity Description

Podium to Practice™ is an exclusive accredited continuing education activity featuring two myeloproliferative neoplasms (MPN) experts who provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASH Annual Meeting.

Statement of Educational Need

In recent years, there have been major advances in our understanding of the underlying genetic changes that drive the development of MPNs, particularly with the discovery of mutations in the Janus kinase 2 (JAK2), thrombopoietin receptor (MPL), and calreticulin (CALR) genes. JAK inhibitors represent a shift in the treatment paradigm from largely managing lifestyle and cardiovascular risk factors and addressing the effects of the disease, to attempting modification of the disease process itself. Despite these advances, nearly all treatment options for MPNs are not curative. Therefore, reduction of symptom burden, and thereby the impact of MPNs on QoL, is critical and should be considered a major goal of treatment. With a robust pipeline of new disease-modifying therapies, a clinical question of whether to aim for a deeper response is emerging.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
John O. Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Consultant: AbbVie, Bristol Myers Squibb, Celgene Corporation, Constellation, CTI BioPharma, Geron, Incyte Corporation, Kartos, Novartis, PharmaEssentia, Roche, Sierra ONC
Contracted Research: AbbVie, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma, Geron, Incyte Corporation, Kartos, Novartis, PharmaEssentia, Roche


Alessandro Vannucchi, MD
Professor of Hematology
Careggi University Hospital
University of Florence
Florence, Italy

Consultant: AbbVie, Blueprint, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Roche
Contracted Research: AbbVie, Blueprint, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Roche

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by an independent educational grant from CTI BioPharma.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Sagar Lonial, MD, FACP
0.25 CME
University of Nebraska Medical Center
Expert Insights − Experts Debate: Treatment Decisions in Relapsed/Refractory Multiple Myeloma

Expert Insights − Experts Debate: Treatment Decisions in Relapsed/Refractory Multiple Myeloma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: February 2, 2022
Expires: February 2, 2023
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
  • Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Expert Insights is an interview involving two renowned experts actively engaged in the treatment of patients with relapsed/refractory multiple myeloma. Don’t miss the opportunity to watch Drs. Sagar Lonial and Krina Patel as they provide key highlights from a satellite symposium preceding the 2021 ASH Annual Meeting.

Statement of Educational Need

The treatment of multiple myeloma (MM) has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory (RR) MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data on investigational agents will require expert guidance and interpretation of newly released data. The goal of this satellite symposium is to provide actionable information and knowledge that will ensure clinicians use the most up-to-date strategies for treating patients with RR MM.

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Consulting Fees: Amgen Inc., Bluebird, Bristol Myers Squibb Company, Celgene Corporation, Genentech, Novartis, Sanofi, Takeda Oncology
Other: Board of Directors TG Therapeutics with stock


Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Consulting Fees: Arcellx, Bristol Myers Squibb Company, Janssen, Pfizer

Planning Committee

The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Jennifer Bechan, CMP, HMCC; Dru Dace, PhD; Kraig Steubing

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.

Statement of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: February 2, 2022
Expires: February 2, 2023
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
  • Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Expert Insights is an interview involving two renowned experts actively engaged in the treatment of patients with relapsed/refractory multiple myeloma. Don’t miss the opportunity to watch Drs. Sagar Lonial and Krina Patel as they provide key highlights from a satellite symposium preceding the 2021 ASH Annual Meeting.

Statement of Educational Need

The treatment of multiple myeloma (MM) has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory (RR) MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data on investigational agents will require expert guidance and interpretation of newly released data. The goal of this satellite symposium is to provide actionable information and knowledge that will ensure clinicians use the most up-to-date strategies for treating patients with RR MM.

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Consulting Fees: Amgen Inc., Bluebird, Bristol Myers Squibb Company, Celgene Corporation, Genentech, Novartis, Sanofi, Takeda Oncology
Other: Board of Directors TG Therapeutics with stock


Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Consulting Fees: Arcellx, Bristol Myers Squibb Company, Janssen, Pfizer

Planning Committee

The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Jennifer Bechan, CMP, HMCC; Dru Dace, PhD; Kraig Steubing

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.

Statement of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Jennifer Woyach, MD
0.5 CME
Postgraduate Institute for Medicine
Podium to Practice: Clinical Updates for the Treatment of Patients with CLL from the 2021 Annual Hematology Meeting

Podium to Practice: Clinical Updates for the Treatment of Patients with CLL from the 2021 Annual Hematology Meeting

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 1, 2022
Expires: February 1, 2023
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review how patient and disease-related factors such as patient age, performance status, comorbidities, and mutational status impact the choice of therapy for patients with CLL
  • Evaluate recent clinical trial data on the safety and efficacy of current and emerging agents and regimens for patients with newly diagnosed CLL
  • Assess various approaches to the treatment of patients with relapsed/refractory CLL, including the optimal sequencing of agents

Activity Description

Podium to Practice™ is an exclusive accredited continuing education activity featuring two chronic lymphocytic leukemia (CLL) experts who provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASH Annual Meeting.

Statement of Educational Need

With an age‐adjusted incidence of 4.1/100,000 inhabitants in the United States, chronic lymphocytic leukemia (CLL) is the most common type of leukemia in western countries. The natural history of CLL is variable, and outcomes are influenced by multiple patient and disease-related factors. Given the heterogeneity of the disease, there is no “one size fits all” recommendation. Clinicians need to be aware of the multiple patient and disease-related factors that impact selection of therapy for patients with CLL and need expert guidance on the selection of optimal frontline treatment approaches for their patients with CLL.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
Jennifer Woyach, MD

The James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Consultant: AbbVie, Arqule, AstraZeneca, BeiGene, Janssen, Loxo, Morphosys, and Pharmacyclics
Contracted Research: AbbVie, Karyopharm, Loxo, Morphosys, and Verastem


Matthew S. Davids, MD, MMSc
Director, Clinical Research, Division of Lymphoma
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Consultant: Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lily, Genentech, Janssen, Merck, Ono Pharmaceuticals, Pharmacyclics, Research to Practice, Takeda, TG Therapeutics, Verastem, and Zentalis
Contracted Research: Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 1, 2022
Expires: February 1, 2023
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review how patient and disease-related factors such as patient age, performance status, comorbidities, and mutational status impact the choice of therapy for patients with CLL
  • Evaluate recent clinical trial data on the safety and efficacy of current and emerging agents and regimens for patients with newly diagnosed CLL
  • Assess various approaches to the treatment of patients with relapsed/refractory CLL, including the optimal sequencing of agents

Activity Description

Podium to Practice™ is an exclusive accredited continuing education activity featuring two chronic lymphocytic leukemia (CLL) experts who provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASH Annual Meeting.

Statement of Educational Need

With an age‐adjusted incidence of 4.1/100,000 inhabitants in the United States, chronic lymphocytic leukemia (CLL) is the most common type of leukemia in western countries. The natural history of CLL is variable, and outcomes are influenced by multiple patient and disease-related factors. Given the heterogeneity of the disease, there is no “one size fits all” recommendation. Clinicians need to be aware of the multiple patient and disease-related factors that impact selection of therapy for patients with CLL and need expert guidance on the selection of optimal frontline treatment approaches for their patients with CLL.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
Jennifer Woyach, MD

The James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Consultant: AbbVie, Arqule, AstraZeneca, BeiGene, Janssen, Loxo, Morphosys, and Pharmacyclics
Contracted Research: AbbVie, Karyopharm, Loxo, Morphosys, and Verastem


Matthew S. Davids, MD, MMSc
Director, Clinical Research, Division of Lymphoma
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Consultant: Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lily, Genentech, Janssen, Merck, Ono Pharmaceuticals, Pharmacyclics, Research to Practice, Takeda, TG Therapeutics, Verastem, and Zentalis
Contracted Research: Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Pages